Heartsciences INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
Heart Test Laboratories aims to raise capital through a new stock and warrant offering to fund FDA clearance efforts and commercial development of its AI-ECG technology.
NASDAQ
Heart Test Laboratories is registering the resale of up to 34,684,859 shares of its common stock by selling stockholders, including shares issued to Mount Sinai, Lincoln Park Capital, John Q. Adams, and Matthews Southwest Holdings.